Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P O'Neill

Showing results (721-730 of 799) with videos related to

Pageof 80
Sort By:
Cells|January 16, 2020
Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast CancerBrian M Moloney, Katie E Gilligan, Doireann P Joyce, et al.
Head & Neck|July 10, 2024
Airway decision making in major head and neck surgery: Irish multicenter, multidisciplinary recommendationsEoin F Cleere, Christopher Read, Sarah Prunty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres AloneKaren T Brown, Richard K Do, Mithat Gonen, et al.
The Journal of Biological Chemistry|June 14, 2000
Characterization of the human cysteinyl leukotriene 2 receptorC E Heise, B F O'Dowd, D J Figueroa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2015
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysisB Kasenda, A J M Ferreri, E Marturano, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Journal of Neurochemistry|December 1, 1998
Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3L F Kolakowski, G P O'Neill, A D Howard, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
Neuro-Oncology|August 29, 2014
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working GroupBrian M Alexander, Evanthia Galanis, W K Alfred Yung, et al.
Nature|July 3, 1999
Characterization of the human cysteinyl leukotriene CysLT1 receptorK R Lynch, G P O'Neill, Q Liu, et al.
Pageof 80

Showing results (721-730 of 799) with videos related to

Sort By:
Pageof 80
Cells|January 16, 2020
Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast CancerBrian M Moloney, Katie E Gilligan, Doireann P Joyce, et al.
Head & Neck|July 10, 2024
Airway decision making in major head and neck surgery: Irish multicenter, multidisciplinary recommendationsEoin F Cleere, Christopher Read, Sarah Prunty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres AloneKaren T Brown, Richard K Do, Mithat Gonen, et al.
The Journal of Biological Chemistry|June 14, 2000
Characterization of the human cysteinyl leukotriene 2 receptorC E Heise, B F O'Dowd, D J Figueroa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2015
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysisB Kasenda, A J M Ferreri, E Marturano, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Journal of Neurochemistry|December 1, 1998
Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3L F Kolakowski, G P O'Neill, A D Howard, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
Neuro-Oncology|August 29, 2014
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working GroupBrian M Alexander, Evanthia Galanis, W K Alfred Yung, et al.
Nature|July 3, 1999
Characterization of the human cysteinyl leukotriene CysLT1 receptorK R Lynch, G P O'Neill, Q Liu, et al.
Pageof 80